453 related articles for article (PubMed ID: 34499652)
1. Immunogenic amino acid motifs and linear epitopes of COVID-19 mRNA vaccines.
Wisnewski AV; Redlich CA; Liu J; Kamath K; Abad QA; Smith RF; Fazen L; Santiago R; Campillo Luna J; Martinez B; Baum-Jones E; Waitz R; Haynes WA; Shon JC
PLoS One; 2021; 16(9):e0252849. PubMed ID: 34499652
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
3. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
4. A vaccine built from potential immunogenic pieces derived from the SARS-CoV-2 spike glycoprotein: A computational approximation.
Marchan J
J Immunol Methods; 2022 Mar; 502():113216. PubMed ID: 35007561
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
[TBL] [Abstract][Full Text] [Related]
6. Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2.
Lin L; Ting S; Yufei H; Wendong L; Yubo F; Jing Z
Virus Res; 2020 Oct; 288():198082. PubMed ID: 32621841
[TBL] [Abstract][Full Text] [Related]
7. Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach.
Bhattacharya M; Sharma AR; Patra P; Ghosh P; Sharma G; Patra BC; Lee SS; Chakraborty C
J Med Virol; 2020 Jun; 92(6):618-631. PubMed ID: 32108359
[TBL] [Abstract][Full Text] [Related]
8. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
9. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
[TBL] [Abstract][Full Text] [Related]
10. Immunodominant linear B cell epitopes in the spike and membrane proteins of SARS-CoV-2 identified by immunoinformatics prediction and immunoassay.
Polyiam K; Phoolcharoen W; Butkhot N; Srisaowakarn C; Thitithanyanont A; Auewarakul P; Hoonsuwan T; Ruengjitchatchawalya M; Mekvichitsaeng P; Roshorm YM
Sci Rep; 2021 Oct; 11(1):20383. PubMed ID: 34650130
[TBL] [Abstract][Full Text] [Related]
11. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies.
Barnes CO; West AP; Huey-Tubman KE; Hoffmann MAG; Sharaf NG; Hoffman PR; Koranda N; Gristick HB; Gaebler C; Muecksch F; Lorenzi JCC; Finkin S; Hägglöf T; Hurley A; Millard KG; Weisblum Y; Schmidt F; Hatziioannou T; Bieniasz PD; Caskey M; Robbiani DF; Nussenzweig MC; Bjorkman PJ
Cell; 2020 Aug; 182(4):828-842.e16. PubMed ID: 32645326
[TBL] [Abstract][Full Text] [Related]
12. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients.
Poh CM; Carissimo G; Wang B; Amrun SN; Lee CY; Chee RS; Fong SW; Yeo NK; Lee WH; Torres-Ruesta A; Leo YS; Chen MI; Tan SY; Chai LYA; Kalimuddin S; Kheng SSG; Thien SY; Young BE; Lye DC; Hanson BJ; Wang CI; Renia L; Ng LFP
Nat Commun; 2020 Jun; 11(1):2806. PubMed ID: 32483236
[TBL] [Abstract][Full Text] [Related]
13. Landscape and selection of vaccine epitopes in SARS-CoV-2.
Smith CC; Olsen KS; Gentry KM; Sambade M; Beck W; Garness J; Entwistle S; Willis C; Vensko S; Woods A; Fini M; Carpenter B; Routh E; Kodysh J; O'Donnell T; Haber C; Heiss K; Stadler V; Garrison E; Sandor AM; Ting JPY; Weiss J; Krajewski K; Grant OC; Woods RJ; Heise M; Vincent BG; Rubinsteyn A
Genome Med; 2021 Jun; 13(1):101. PubMed ID: 34127050
[TBL] [Abstract][Full Text] [Related]
14. Reverse vaccinology assisted designing of multiepitope-based subunit vaccine against SARS-CoV-2.
Tahir Ul Qamar M; Shahid F; Aslam S; Ashfaq UA; Aslam S; Fatima I; Fareed MM; Zohaib A; Chen LL
Infect Dis Poverty; 2020 Sep; 9(1):132. PubMed ID: 32938504
[TBL] [Abstract][Full Text] [Related]
15. Limited Recognition of Highly Conserved Regions of SARS-CoV-2.
Swaminathan S; Lineburg KE; Ambalathingal GR; Crooks P; Grant EJ; Mohan SV; Raju J; Panikkar A; Le Texier L; Tong ZWM; Chew KY; Neller MA; Short KR; Gowda H; Gras S; Khanna R; Smith C
Microbiol Spectr; 2022 Feb; 10(1):e0278021. PubMed ID: 35196796
[TBL] [Abstract][Full Text] [Related]
16. The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines.
Chan RWY; Liu S; Cheung JY; Tsun JGS; Chan KC; Chan KYY; Fung GPG; Li AM; Lam HS
Front Immunol; 2021; 12():744887. PubMed ID: 34712232
[TBL] [Abstract][Full Text] [Related]
17. Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses.
Nathan A; Rossin EJ; Kaseke C; Park RJ; Khatri A; Koundakjian D; Urbach JM; Singh NK; Bashirova A; Tano-Menka R; Senjobe F; Waring MT; Piechocka-Trocha A; Garcia-Beltran WF; Iafrate AJ; Naranbhai V; Carrington M; Walker BD; Gaiha GD
Cell; 2021 Aug; 184(17):4401-4413.e10. PubMed ID: 34265281
[TBL] [Abstract][Full Text] [Related]
18. Revelation of Potent Epitopes Present in Unannotated ORF Antigens of SARS-CoV-2 for Epitope-Based Polyvalent Vaccine Design Using Immunoinformatics Approach.
Uttamrao PP; Sathyaseelan C; Patro LPP; Rathinavelan T
Front Immunol; 2021; 12():692937. PubMed ID: 34497604
[TBL] [Abstract][Full Text] [Related]
19. A new testing platform using fingerstick blood for quantitative antibody response evaluation after SARS-CoV-2 vaccination.
Du J; Zhang D; Pathakamuri JA; Kuebler D; Yang Y; Loginova Y; Chu E; Madej R; Neves JV; Singer B; Radke H; Spencer N; Rizk E; Zhang A; Lu CM; Sha MY
Emerg Microbes Infect; 2022 Dec; 11(1):250-259. PubMed ID: 34951566
[TBL] [Abstract][Full Text] [Related]
20. Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches.
Safavi A; Kefayat A; Mahdevar E; Abiri A; Ghahremani F
Vaccine; 2020 Nov; 38(48):7612-7628. PubMed ID: 33082015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
